Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Chitotriosidase, a marker of innate immunity, is elevated in patients with primary breast cancer.

Thein MS, Kohli A, Ram R, Ingaramo MC, Jain A, Fedarko NS.

Cancer Biomark. 2017 Jul 4;19(4):383-391. doi: 10.3233/CBM-160101.

2.

Discovery and Validation of Agonistic Angiotensin Receptor Autoantibodies as Biomarkers of Adverse Outcomes.

Abadir PM, Jain A, Powell LJ, Xue QL, Tian J, Hamilton RG, Bennett DA, Finucane T, Walston JD, Fedarko NS.

Circulation. 2017 Jan 31;135(5):449-459. doi: 10.1161/CIRCULATIONAHA.116.022385. Epub 2016 Nov 30.

3.

Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type.

El-Maouche D, Dumitrescu CE, Andreopoulou P, Gafni RI, Brillante BA, Bhattacharyya N, Fedarko NS, Collins MT.

Osteoporos Int. 2016 Jul;27(7):2345-2353. doi: 10.1007/s00198-016-3543-5. Epub 2016 Feb 29.

PMID:
26928188
4.

Osteoblast function and bone histomorphometry in a murine model of Rett syndrome.

Blue ME, Boskey AL, Doty SB, Fedarko NS, Hossain MA, Shapiro JR.

Bone. 2015 Jul;76:23-30. doi: 10.1016/j.bone.2015.01.024. Epub 2015 Mar 10.

PMID:
25769649
5.

The short-term and long-term impact of a brief aging research training program for medical students.

Barron JS, Bragg E, Cayea D, Durso SC, Fedarko NS.

Gerontol Geriatr Educ. 2015;36(1):96-106. doi: 10.1080/02701960.2014.942036. Epub 2014 Aug 8.

6.

WISP1/CCN4: a potential target for inhibiting prostate cancer growth and spread to bone.

Ono M, Inkson CA, Sonn R, Kilts TM, de Castro LF, Maeda A, Fisher LW, Robey PG, Berendsen AD, Li L, McCartney-Francis N, Brown AC, Crawford NP, Molinolo A, Jain A, Fedarko NS, Young MF.

PLoS One. 2013 Aug 14;8(8):e71709. doi: 10.1371/journal.pone.0071709. eCollection 2013.

7.

Serum chitotriosidase, a putative marker of chronically activated macrophages, increases with normal aging.

Ramanathan R, Kohli A, Ingaramo MC, Jain A, Leng SX, Punjabi NM, Walston JD, Fedarko NS.

J Gerontol A Biol Sci Med Sci. 2013 Oct;68(10):1303-9. doi: 10.1093/gerona/glt022. Epub 2013 Mar 22.

8.

Plasma neopterin level as a marker of peripheral immune activation in amnestic mild cognitive impairment and Alzheimer's disease.

Parker DC, Mielke MM, Yu Q, Rosenberg PB, Jain A, Lyketsos CG, Fedarko NS, Oh ES.

Int J Geriatr Psychiatry. 2013 Feb;28(2):149-54. doi: 10.1002/gps.3802. Epub 2012 Apr 27.

9.

Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.

Gallicchio L, MacDonald R, Wood B, Rushovich E, Fedarko NS, Helzlsouer KJ.

J Bone Miner Res. 2012 Sep;27(9):1959-66. doi: 10.1002/jbmr.1641.

10.

Identification and characterization of a functional mitochondrial angiotensin system.

Abadir PM, Foster DB, Crow M, Cooke CA, Rucker JJ, Jain A, Smith BJ, Burks TN, Cohn RD, Fedarko NS, Carey RM, O'Rourke B, Walston JD.

Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14849-54. doi: 10.1073/pnas.1101507108. Epub 2011 Aug 18.

11.

IL-6-independent association of elevated serum neopterin levels with prevalent frailty in community-dwelling older adults.

Leng SX, Tian X, Matteini A, Li H, Hughes J, Jain A, Walston JD, Fedarko NS.

Age Ageing. 2011 Jul;40(4):475-81. doi: 10.1093/ageing/afr047. Epub 2011 May 17.

12.

The biology of aging and frailty.

Fedarko NS.

Clin Geriatr Med. 2011 Feb;27(1):27-37. doi: 10.1016/j.cger.2010.08.006.

13.

"Speed dating" as a technique to efficiently align mentees and mentors in a geriatrics training program.

McNabney MK, Fedarko NS, Durso SC.

J Am Geriatr Soc. 2010 Nov;58(11):2245-6. doi: 10.1111/j.1532-5415.2010.03149.x. No abstract available.

PMID:
21054319
14.

Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-β in plasma.

Oh ES, Mielke MM, Rosenberg PB, Jain A, Fedarko NS, Lyketsos CG, Mehta PD.

J Alzheimers Dis. 2010;21(3):769-73. doi: 10.3233/JAD-2010-100456.

15.

Serum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fat.

Spencer ME, Jain A, Matteini A, Beamer BA, Wang NY, Leng SX, Punjabi NM, Walston JD, Fedarko NS.

J Gerontol A Biol Sci Med Sci. 2010 Aug;65(8):858-65. doi: 10.1093/gerona/glq066. Epub 2010 May 17.

16.

Serum markers of apoptosis decrease with age and cancer stage.

Kavathia N, Jain A, Walston J, Beamer BA, Fedarko NS.

Aging (Albany NY). 2009 Jul 14;1(7):652-63.

17.

Small integrin-binding proteins as serum markers for prostate cancer detection.

Jain A, McKnight DA, Fisher LW, Humphreys EB, Mangold LA, Partin AW, Fedarko NS.

Clin Cancer Res. 2009 Aug 15;15(16):5199-207. doi: 10.1158/1078-0432.CCR-09-0783. Epub 2009 Aug 11.

18.

Surgical blood loss during femoral rodding in children with osteogenesis imperfecta.

Pichard CP, Robinson RE, Skolasky RL, Fedarko NS, Leet AI.

J Child Orthop. 2009 Aug;3(4):301-5. doi: 10.1007/s11832-009-0190-9. Epub 2009 Jul 30.

19.

Upregulated monocytic expression of CXC chemokine ligand 10 (CXCL-10) and its relationship with serum interleukin-6 levels in the syndrome of frailty.

Qu T, Yang H, Walston JD, Fedarko NS, Leng SX.

Cytokine. 2009 Jun;46(3):319-24. doi: 10.1016/j.cyto.2009.02.015. Epub 2009 Apr 1.

20.

Upregulated ex vivo expression of stress-responsive inflammatory pathway genes by LPS-challenged CD14(+) monocytes in frail older adults.

Qu T, Walston JD, Yang H, Fedarko NS, Xue QL, Beamer BA, Ferrucci L, Rose NR, Leng SX.

Mech Ageing Dev. 2009 Mar;130(3):161-6. doi: 10.1016/j.mad.2008.10.005. Epub 2008 Nov 5.

21.

ELISA and multiplex technologies for cytokine measurement in inflammation and aging research.

Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA.

J Gerontol A Biol Sci Med Sci. 2008 Aug;63(8):879-84. Review.

22.

Structural requirements for bone sialoprotein binding and modulation of matrix metalloproteinase-2.

Jain A, Karadag A, Fisher LW, Fedarko NS.

Biochemistry. 2008 Sep 23;47(38):10162-70. doi: 10.1021/bi801068p. Epub 2008 Aug 26.

23.
24.

Impact on bone of an estrogen receptor-alpha gene loss of function mutation.

Smith EP, Specker B, Bachrach BE, Kimbro KS, Li XJ, Young MF, Fedarko NS, Abuzzahab MJ, Frank GR, Cohen RM, Lubahn DB, Korach KS.

J Clin Endocrinol Metab. 2008 Aug;93(8):3088-96. doi: 10.1210/jc.2007-2397. Epub 2008 May 27.

25.

Bone sialoprotein binding to matrix metalloproteinase-2 alters enzyme inhibition kinetics.

Jain A, Fisher LW, Fedarko NS.

Biochemistry. 2008 Jun 3;47(22):5986-95. doi: 10.1021/bi800133n. Epub 2008 May 8.

26.

T-lymphocytes expressing CC chemokine receptor-5 are increased in frail older adults.

De Fanis U, Wang GC, Fedarko NS, Walston JD, Casolaro V, Leng SX.

J Am Geriatr Soc. 2008 May;56(5):904-8. doi: 10.1111/j.1532-5415.2008.01673.x. Epub 2008 Apr 1.

27.

Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS.

Nat Rev Cancer. 2008 Mar;8(3):212-26. doi: 10.1038/nrc2345. Review.

28.

Determination of the elimination half-life of fibroblast growth factor-23.

Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, Wodajo FM, Fedarko NS, Collins MT.

J Clin Endocrinol Metab. 2007 Jun;92(6):2374-7. Epub 2007 Mar 20.

PMID:
17374707
29.

Activation of (Na+ + K+)-ATPase induces positive inotropy in intact mouse heart in vivo.

Xu KY, Takimoto E, Fedarko NS.

Biochem Biophys Res Commun. 2006 Oct 20;349(2):582-7. Epub 2006 Aug 22.

PMID:
16949050
30.

The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.

Garringer HJ, Fisher C, Larsson TE, Davis SI, Koller DL, Cullen MJ, Draman MS, Conlon N, Jain A, Fedarko NS, Dasgupta B, White KE.

J Clin Endocrinol Metab. 2006 Oct;91(10):4037-42. Epub 2006 Jul 25.

PMID:
16868048
31.

Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer.

Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang B, Michalowska AM, Fisher LW, Fedarko NS, Jain A, Pinkas J, Lonning S, Wakefield LM.

Cancer Res. 2006 Jun 15;66(12):6327-35.

32.
33.

Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.

Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS, Liu J, Fedarko NS, Winer KK.

J Bone Miner Res. 2005 Nov;20(11):1944-50. Epub 2005 Jul 18.

34.

Aging and protein expression.

Fedarko NS.

J Musculoskelet Neuronal Interact. 2002 Dec;2(6):584-9. No abstract available.

35.

Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers.

Fisher LW, Jain A, Tayback M, Fedarko NS.

Clin Cancer Res. 2004 Dec 15;10(24):8501-11.

36.

Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density.

Jain A, Fedarko NS, Collins MT, Gelman R, Ankrom MA, Tayback M, Fisher LW.

J Clin Endocrinol Metab. 2004 Aug;89(8):4158-61.

PMID:
15292364
37.

Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion.

Karadag A, Ogbureke KU, Fedarko NS, Fisher LW.

J Natl Cancer Inst. 2004 Jun 16;96(12):956-65.

PMID:
15199115
38.

Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.

Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ, Goggins M.

Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91.

39.

Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases.

Fedarko NS, Jain A, Karadag A, Fisher LW.

FASEB J. 2004 Apr;18(6):734-6. Epub 2004 Feb 6.

PMID:
14766790
40.

FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P.

J Clin Invest. 2003 Sep;112(5):683-92.

41.

Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins.

Fisher LW, Fedarko NS.

Connect Tissue Res. 2003;44 Suppl 1:33-40.

PMID:
12952171
42.

Age-related changes in human bone proteoglycan structure. Impact of osteogenesis imperfecta.

Grzesik WJ, Frazier CR, Shapiro JR, Sponseller PD, Robey PG, Fedarko NS.

J Biol Chem. 2002 Nov 15;277(46):43638-47. Epub 2002 Sep 6.

43.
44.

Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.

Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW.

Clin Cancer Res. 2001 Dec;7(12):4060-6.

45.

Purification of proteoglycans from mineralized tissues.

Fedarko NS.

Methods Mol Biol. 2001;171:19-25. No abstract available.

PMID:
11450229
46.

Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin.

Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS.

Biochem Biophys Res Commun. 2001 Jan 19;280(2):460-5.

PMID:
11162539
47.

Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis.

Bellahcène A, Bonjean K, Fohr B, Fedarko NS, Robey FA, Young MF, Fisher LW, Castronovo V.

Circ Res. 2000 Apr 28;86(8):885-91.

PMID:
10785511
48.

Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack.

Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW.

J Biol Chem. 2000 Jun 2;275(22):16666-72.

49.

Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts.

Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM.

J Pharmacol Exp Ther. 2000 Mar;292(3):988-94.

PMID:
10688614
50.

Receptor tyrosine kinase expression in human bone marrow stromal cells.

Satomura K, Derubeis AR, Fedarko NS, Ibaraki-O'Connor K, Kuznetsov SA, Rowe DW, Young MF, Gehron Robey P.

J Cell Physiol. 1998 Dec;177(3):426-38.

PMID:
9808151

Supplemental Content

Loading ...
Support Center